Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MYGN 
Myriad Genetics Inc (MYGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MYGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $7.38
1 Year Target Price $7.38
| 3 | Strong Buy |
| 3 | Buy |
| 6 | Hold |
| 2 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.95% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 578.74M USD | Price to earnings Ratio - | 1Y Target Price 7.38 |
Price to earnings Ratio - | 1Y Target Price 7.38 | ||
Volume (30-day avg) 15 | Beta 1.9 | 52 Weeks Range 3.76 - 29.30 | Updated Date 08/29/2025 |
52 Weeks Range 3.76 - 29.30 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.01 | Actual 0.05 |
Profitability
Profit Margin -47.45% | Operating Margin (TTM) -5.87% |
Management Effectiveness
Return on Assets (TTM) -5.44% | Return on Equity (TTM) -70.03% |
Valuation
Trailing PE - | Forward PE 3333.33 | Enterprise Value 658937579 | Price to Sales(TTM) 0.69 |
Enterprise Value 658937579 | Price to Sales(TTM) 0.69 | ||
Enterprise Value to Revenue 0.79 | Enterprise Value to EBITDA -23.47 | Shares Outstanding 93044600 | Shares Floating 85688519 |
Shares Outstanding 93044600 | Shares Floating 85688519 | ||
Percent Insiders 2.84 | Percent Institutions 98.31 |
Upturn AI SWOT
Myriad Genetics Inc
Company Overview
History and Background
Myriad Genetics Inc. was founded in 1991. It focuses on genetic testing and precision medicine, with significant milestones including the development of the BRCA1/2 test for breast and ovarian cancer risk and expanding into other areas like hereditary cancer, pharmacogenomics, and prenatal testing.
Core Business Areas
- Hereditary Cancer Testing: Offers tests to assess an individual's risk for developing certain cancers, including breast, ovarian, colon, and prostate cancer. Key tests include myRisk Hereditary Cancer and BRACAnalysis.
- Pharmacogenomics: Provides GeneSight Psychotropic, a test that helps healthcare providers determine which medications may work best for patients with depression, anxiety, and other psychiatric conditions based on their genetic makeup.
- Prenatal Testing: Offers Prequel Prenatal Screen, a non-invasive prenatal screening (NIPS) test that assesses the risk of certain chromosomal abnormalities in a fetus.
Leadership and Structure
Paul Diaz is the President and CEO. The company has a typical corporate structure with a board of directors overseeing management.
Top Products and Market Share
Key Offerings
- myRisk Hereditary Cancer: A multigene panel test assessing risk for eight common cancers. While specific market share data is not readily available, it competes with other multigene panel providers. Competitors include Invitae and Ambry Genetics (now part of Konica Minolta).
- GeneSight Psychotropic: A pharmacogenomic test used to guide antidepressant treatment. While specific market share data is not available, it is a leading test in its category. Competitors include Assurex Health (now part of Myriad).
- Prequel Prenatal Screen: A non-invasive prenatal screening test. Competitors include Natera (NTRA) and Illumina (ILMN).
Market Dynamics
Industry Overview
The genetic testing market is experiencing rapid growth due to technological advancements, increased awareness, and the growing adoption of precision medicine. The industry is highly competitive and regulated.
Positioning
Myriad Genetics Inc. is a key player in the genetic testing market, particularly in hereditary cancer and pharmacogenomics. Its competitive advantages include its established brand, proprietary technology, and strong relationships with healthcare providers.
Total Addressable Market (TAM)
The global genetic testing market is projected to reach hundreds of billions by 2030. Myriad is well-positioned to capture a portion of this TAM through its existing product lines and potential expansion into new areas.
Upturn SWOT Analysis
Strengths
- Established brand recognition
- Proprietary technology and intellectual property
- Extensive database of genetic information
- Strong relationships with healthcare providers
- Diverse product portfolio
Weaknesses
- Reliance on a few key products
- Exposure to changing reimbursement policies
- Litigation risk related to patent protection
- Competition from larger, more diversified companies
Opportunities
- Expanding into new geographic markets
- Developing new genetic tests for other diseases
- Partnering with pharmaceutical companies to develop companion diagnostics
- Leveraging data analytics to improve patient outcomes
Threats
- Increased competition from other genetic testing companies
- Changes in reimbursement policies that reduce payments for genetic tests
- Negative publicity related to the accuracy or utility of genetic tests
- Data privacy and security breaches
Competitors and Market Share
Key Competitors
- ILMN
- NTRA
- LH
- DGX
Competitive Landscape
Myriad Genetics Inc. faces intense competition in the genetic testing market. Illumina and Natera, for example, have significant market share in certain segments. The company's ability to innovate and maintain its competitive advantages will be crucial for future success.
Major Acquisitions
Counsyl (Assurex Health previously)
- Year: 2018
- Acquisition Price (USD millions): 375
- Strategic Rationale: Expanded Myriad's prenatal testing and pharmacogenomics capabilities.
Growth Trajectory and Initiatives
Historical Growth: Past growth depended on key product performance.
Future Projections: Analyst estimates can be found on financial news sites. (Actual data unavailable for real-time update)
Recent Initiatives: Recent initiatives may include product launches or strategic partnerships.
Summary
Myriad Genetics is a key player in genetic testing, but faces strong competition and reliance on key products. Strengths include their brand recognition and proprietary technology. Threats include reimbursement policy changes and data privacy concerns. To maintain growth, the company should focus on innovation and strategic partnerships. Overall, Myriad's future success depends on its ability to adapt to the evolving genetic testing landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Myriad Genetics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 1995-10-05 | President, CEO & Director Mr. Samraat S. Raha | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2700 | Website https://www.myriad.com |
Full time employees 2700 | Website https://www.myriad.com | ||
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.